Immunomedics (NASDAQ:IMMU) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Several other equities research analysts have also weighed in on the stock. Jefferies Group upped their target price on shares of Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Wednesday, October 4th. Finally, BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $15.33.

Immunomedics (NASDAQ IMMU) traded down $0.22 on Friday, hitting $15.50. 2,185,100 shares of the stock traded hands, compared to its average volume of 3,660,000. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics has a fifty-two week low of $3.30 and a fifty-two week high of $17.05. The company has a market cap of $2,360.00, a price-to-earnings ratio of -6.92 and a beta of 1.48.

In related news, Director Venbio Select Advisor Llc purchased 1,150,000 shares of Immunomedics stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Behzad Aghazadeh purchased 1,325,000 shares of Immunomedics stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average price of $10.47 per share, for a total transaction of $13,872,750.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank lifted its position in Immunomedics by 8.1% during the 2nd quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares in the last quarter. Stephens Inc. AR acquired a new position in Immunomedics during the 2nd quarter worth about $115,000. Raymond James Financial Services Advisors Inc. lifted its position in Immunomedics by 11.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares in the last quarter. SG Americas Securities LLC lifted its position in Immunomedics by 99.3% during the 2nd quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 10,323 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Immunomedics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 1,747 shares in the last quarter. Institutional investors and hedge funds own 76.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/05/immunomedics-immu-downgraded-by-valuengine-to-sell.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.